

# Links between gut microbiome composition and fatty liver disease in a large population sample

Matti O. Ruuskanen<sup>1,2\*</sup>, Fredrik Åberg<sup>3,4</sup>, Ville Männistö<sup>5,6</sup>, Aki S. Havulinna<sup>2,7</sup>, Guillaume Méric<sup>8,9</sup>, Yang Liu<sup>8,10</sup>, Rohit Loomba<sup>11,12</sup>, Yoshiki Vázquez-Baeza<sup>13,14</sup>, Anupriya Tripathi<sup>15,16,17</sup>, Liisa M. Valsta<sup>2</sup>, Michael Inouye<sup>8,18</sup>, Pekka Jousilahti<sup>2</sup>, Veikko Salomaa<sup>2</sup>, Mohit Jain<sup>12,19</sup>, Rob Knight<sup>13,14,20,21</sup>, Leo Lahti<sup>22</sup>, Teemu J. Niiranen<sup>1,2,23</sup>

<sup>1</sup>Department of Internal Medicine, University of Turku, Turku, Finland

<sup>2</sup>Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland

<sup>3</sup>Transplantation and Liver Surgery Clinic, Helsinki University Hospital, University of Helsinki, Helsinki, Finland

<sup>4</sup>The Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

<sup>5</sup>Department of Medicine, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland

<sup>6</sup>Department of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

<sup>7</sup>Institute for Molecular Medicine Finland, FIMM - HiLIFE, Helsinki, Finland

<sup>8</sup>Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia

<sup>9</sup>Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia

<sup>10</sup>Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia

<sup>11</sup>Department of Medicine, NAFLD Research Center, La Jolla, CA, USA

<sup>12</sup>Department of Medicine, University of California, San Diego, La Jolla, CA, USA

<sup>13</sup>Jacobs School of Engineering, University of California, San Diego, La Jolla, CA, USA

<sup>14</sup>Center for Microbiome Innovation, University of California San Diego, La Jolla, California, USA

<sup>15</sup>Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA

<sup>16</sup>Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA

<sup>17</sup>Division of Biological Sciences, University of California, San Diego, La Jolla, California, USA

<sup>18</sup>Department of Public Health and Primary Care, Cambridge University, Cambridge, United Kingdom

<sup>19</sup>Department of Pharmacology, University of California San Diego, La Jolla, California, USA

<sup>20</sup>Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA

<sup>21</sup>Department of Computer Science & Engineering, University of California San Diego, La Jolla, California, USA

<sup>22</sup>Department of Future Technologies, University of Turku, Turku, Finland

<sup>23</sup>Division of Medicine, Turku University Hospital, Turku, Finland

\*Correspondence: Matti Ruuskanen, [matti.ruuskanen@utu.fi](mailto:matti.ruuskanen@utu.fi)

Running head: Gut microbiome composition and fatty liver

## 39 **Abstract**

40 **Background.** Fatty liver disease is the most common liver disease in the world. It is characterized by a  
41 build-up of excess fat in the liver that can lead to cirrhosis and liver failure. The link between fatty liver  
42 disease and gut microbiome has been known for at least 80 years. However, this association remains  
43 mostly unstudied in the general population because of underdiagnosis and small sample sizes. To  
44 address this knowledge gap, we studied the link between the Fatty Liver Index (FLI), a well-established  
45 proxy for fatty liver disease, and gut microbiome composition in a representative, ethnically  
46 homogeneous population sample in Finland. We based our models on biometric covariates and  
47 phylogenetically transformed gut microbiome compositions from shallow metagenome sequencing.

48 **Results.** Our classification models were able to discriminate between individuals with a high FLI ( $\geq$   
49 60, indicates likely liver steatosis) and low FLI ( $< 60$ ) in our validation set, consisting of 30% of the  
50 data not used in model training, with an average AUC of 0.75. In addition to age and sex, our models  
51 included differences in 11 microbial groups from class *Clostridia*, mostly belonging to orders  
52 *Lachnospirales* and *Oscillospirales*. Pathway analysis of representative genomes of the FLI-associated  
53 taxa in (NCBI) *Clostridium* subclusters IV and XIVa indicated the presence of *e.g.*, ethanol  
54 fermentation pathways.

55 **Conclusions.** Through modeling the fatty liver index, our results provide with high resolution  
56 associations between gut microbiota composition and fatty liver in a large representative population  
57 cohort. Our results lend further support to the role of endogenous ethanol producers in the development  
58 of fatty liver.

59

60 **Keywords: Metagenomics, human gut, fatty liver, fatty liver index, population sample**

## 61 **Background**

62 Fatty liver disease affects roughly a quarter of the world's population (Younossi et al., 2016). It is  
63 characterized by accumulation of fat in the liver cells and is intimately linked with pathophysiology of  
64 metabolic syndrome (Marchesini et al., 2003; Chalasani et al., 2012; Yki-Järvinen, 2014). Fatty liver  
65 disease can be broadly divided into two variants: non-alcoholic fatty liver disease (NAFLD), attributed  
66 to high caloric intake, and alcohol associated fatty liver disease, attributed to high alcohol consumption.  
67 Even though the rate of progressions and underlying causes of both diseases might be different, they  
68 can be broadly sub-divided into those who have fat accumulation in the liver with no or minimal  
69 inflammation or those who have additional features of cellular injury and active inflammation with or  
70 without fibrosis typically seen in peri-sinusoidal area. (Toshikuni et al., 2014). Patients with  
71 steatohepatitis may progress to cirrhosis and hepatocellular carcinoma and have increased risk of liver-  
72 related morbidity and mortality, globally amounting to hundreds of thousands of deaths (Rinella and  
73 Charlton, 2016).

74  
75 The human gut harbors up to  $10^{12}$  microbes per gram of content (Gilbert et al., 2018) and is intimately  
76 connected with the liver. Thus, it is no surprise that gut microbiome composition appears to have a  
77 strong connection with liver disease (Caussy et al., 2019). Numerous studies over the past 80 years  
78 have reported associations between gut microbial composition and liver disease (Compare et al., 2012).  
79 For example, gut permeability and overgrowth of bacteria in the small intestine (Miele et al., 2009),  
80 changes in *Gammaproteobacteria* and *Erysipelotrichi* abundance during choline deficiency (Spencer et  
81 al., 2011), elevated abundance of ethanol-producing bacteria (Zhu et al., 2013; Yuan et al., 2019),  
82 metagenomic signatures of specific bacterial species (Loomba et al., 2017; Jiao et al., 2019) have all  
83 been linked to NAFLD in small case-control patient samples. However, the microbial signatures often  
84 overlap between NAFLD and metabolic diseases, while those of more serious liver disease such as

85 steatohepatitis and cirrhosis are more clear (Aron-Wisniewsky et al., 2020). For example, oral taxa  
86 appear to invade the gut in liver cirrhosis (Qin et al., 2014), and this phenotype can accurately be  
87 detected by analyzing the fecal microbiome composition (AUC = 0.87 in a validation cohort; Caussy et  
88 al., 2019). Furthermore, we recently demonstrated good prediction accuracy for incident liver disease  
89 diagnoses (AUC = 0.83 for non-alcoholic liver disease, AUC = 0.96 for alcoholic liver disease, during  
90 ~15 years), showing that the signatures of serious future liver disease are easy to detect (Liu et al.,  
91 2020).

92  
93 The mechanisms underlying the contribution of gut microbiome content with fatty liver disease are  
94 thought to be primarily linked to gut bacterial metabolism. Bacterial metabolites can indeed be  
95 translocated from the gut through the intestinal barrier into the portal vein and transported to the liver,  
96 where they interact with liver cells, and can lead to inflammation and steatosis (Safari and Gérard,  
97 2019). Short-chain fatty acid production, conversion of choline into methylamines, modification of bile  
98 acids (BA) into secondary BA, and ethanol production, all of which are mediated by gut bacteria, are  
99 also known to be aggravating factors for NAFLD (Safari and Gérard, 2019). Recent studies have also  
100 suggested that endogenous ethanol production by gut bacteria could lead to an increase in gut  
101 membrane permeability (Yuan et al., 2019). This can facilitate the translocation of bacterial metabolites  
102 and cell components such as lipopolysaccharides from the gut to the liver, leading to further  
103 inflammation and possible development of NAFLD (Carpino et al., 2019).

104  
105 Liver biopsy assessment is the current gold standard for diagnosis of fatty liver disease and its severity  
106 (Li et al., 2018), but it is also impractical and unethical in a population-based setting. Ultrasound and  
107 MRI based assessment can help detect presence of fatty liver, however, this data is not available in our  
108 cohort. Regardless, recent studies have shown that indices based on anthropometric measurements and

109 standard blood tests can be a reliable tool for non-invasive diagnosis of fatty liver particularly in  
110 population-based epidemiologic studies (Koehler et al., 2013; Vanni and Bugianesi, 2015).  
111 Here, we designed and conducted computational analyses to examine the links between fatty liver and  
112 gut microbiome composition in a representative population sample of 7211 extensively phenotyped  
113 Finnish individuals (Salosensaari et al., 2020). Because fatty liver disease is generally underdiagnosed  
114 in the general population (Alexander et al., 2018), we used population-wide measurements of BMI,  
115 waist circumference, blood triglycerides and gamma-glutamyl-transferase (GGT) to calculate a  
116 previously validated Fatty Liver Index (FLI) for each participant as a proxy for fatty liver (Bedogni et  
117 al., 2006). In parallel, we used shallow shotgun sequencing to analyze gut microbiome composition  
118 (Hillmann et al., 2018), which also enabled the use of phylogenetic and pathway prediction methods. In  
119 this work, we describe high-resolution associations between fatty liver and individual gut microbial  
120 taxa and clades, which are generalizable at the population level.

121

## 122 **Results**

### 123 **Bacterial community structure is correlated with Fatty Liver Index in a population** 124 **sample**

125 To investigate the link between fatty liver disease (using FLI as a proxy; **Figure 1A, 1B**) and gut  
126 microbial composition, we used linear regression (adjusted  $R^2 = 0.29$ ) on the three first principal  
127 component (PC) axes of the fecal bacterial beta-diversity (between individuals), sex, age, and alcohol  
128 to model FLI.  $\log_{10}(\text{FLI})$  significantly correlated with all three bacterial PC axes, sex, age, and alcohol  
129 use (all  $P < 1 \times 10^{-6}$ ). Correlations between FLI and archaeal PC axes were not significant ( $P > 0.05$ ).  
130 The effect size estimate on  $\log_{10}(\text{FLI})$  was a magnitude larger for PC1 ( $0.11 \pm 0.008$ ) than for PC2  
131 ( $0.04 \pm 0.008$ ) and PC3 ( $-0.06 \pm 0.008$ ). The relationships between FLI and the bacterial PC  
132 components representing their beta-diversity are visualized for each of the three components in **Figure**  
Gut microbiome composition and fatty liver

133 **1C.** In our analyses, we classified our reads against the Genome Taxonomy Database (GTDB; Parks et  
134 al., 2018), and thus the taxonomy discussed in this study follows the standardized GTDB taxonomy,  
135 unless otherwise noted.

136

137 Bacterial clades with the highest positive loadings on PC1 (and therefore associated with higher FLI  
138 values) included members of the *Lachnospirales* and *Oscillospirales* taxonomic orders, of the *Bacilli*  
139 class, and of the *Ruminococcaceae*, *Bacteroidaceae* and *Lachnospiraceae* families (**Figure S2**). These  
140 observations led us to further analyses within a machine learning framework to estimate the relative  
141 contributions of individual bacterial taxa to the differences in FLI between study participants.

142

### 143 **Bacterial lineages within the NCBI *Clostridium* subclusters IV and XIVa associate with** 144 **FLI**

145 In our machine learning framework, we used the known covariates in addition to individual archaeal  
146 and bacterial “balances” as the predicting features. Briefly, each balance represents a single internal  
147 node in a phylogenetic tree, and its value is a log-ratio of the abundances of the two clades descending  
148 this node (for details see methods, and Silverman et al., 2017). Continuous FLI and differences  
149 between FLI groups (FLI < 60,  $N = 4359$  and FLI  $\geq 60$ ,  $N = 1910$ ; see **Figures 1A, 1B**) were modeled  
150 with gradient boosting regression or classification using Leave-One-Group-Out Cross-Validation  
151 (LOGOCV) between participants from different regions.

152

153 After feature selection and Bayesian hyperparameter optimization, the correlation between the  
154 predictions of the final regression models (age, sex, self-reported alcohol use, and 18 bacterial balances  
155 as features; each trained on the data from 5/6 regions) and true values in unseen data from the omitted  
156 region averaged  $R^2 = 0.30$  (0.26 – 0.33). After feature selection and optimization, the main

157 classification models (age, sex, and 11 bacterial balances as features; each trained on the data from 5/6  
158 regions) averaged AUC = 0.75 (**Table S1**) and AUPRC = 0.56 (baseline at 0.30; **Table S2**) on (unseen)  
159 test data from the omitted region. Models trained using only the covariates averaged AUC = 0.71  
160 (AUPRC = 0.47) and using only the 11 bacterial balances they averaged AUC = 0.66 (AUPRC = 0.47)  
161 on test data. Alternative models were constructed by excluding participants with FLI between 30 and  
162 60 (N = 1583) and discerning between groups of  $FLI < 30$  (N = 2776) and  $FLI \geq 60$  (N = 1910). These  
163 models averaged AUC = 0.80 (AUPRC = 0.75, baseline at 0.41) on their respective test data. They  
164 averaged AUC = 0.76 (AUPRC = 0.68) when using only the covariates, and AUC = 0.70 (AUPRC =  
165 0.63) when using only the 20 bacterial balances.

166

167 Because training data from all 6 regions was used to prevent overfitting in the selection of core features  
168 for all of the models, and similarly in searching for common hyperparameters, participants from the  
169 validation region of each model (in the training partition) partly influenced these parameters. Thus, we  
170 also constructed classification models discerning between the  $FLI < 60$  and  $FLI \geq 60$  groups, where  
171 data of the validation region was completely excluded in the feature selection and hyperparameter  
172 optimization of each LOGOCV model. These models, using their individual feature sets and  
173 hyperparameters, averaged AUC = 0.75 and AUPRC = 0.57 (baseline at 0.30) on test data from their  
174 respective validation regions (**Table S3**). Using only covariates, they averaged AUC = 0.71 (AUPRC =  
175 0.47), and AUC = 0.67 (AUPRC = 0.48) with only the bacterial balances.

176

177 To facilitate interpretability of the results, we primarily continued examining the main classification  
178 models using a common set of core features. In these models, the median effect sizes of the features on  
179 the model predictions at their minimum and maximum values were highest for age, followed by sex,  
180 and the 11 balances in the phylogenetic tree (**Figures S2, S3**). All 11 associated balances were in



181 phylum *Firmicutes*, class *Clostridia*, and largely in the NCBI *Clostridium* subclusters IV and XIVa  
182 (**Figure 2**). The specific taxa represented standardized GTDB genera (NCBI in brackets)  
183 *Negativibacillus* (*Clostridium*), *Clostridium M* (*Lachnoclostridium* / *Clostridium*), *CAG-81*  
184 (*Clostridium*), *Dorea* (*Merdimonas* / *Mordavella* / *Dorea* / *Clostridium* / *Eubacterium*), *Faecalicatena*  
185 (*Blautia* / *Ruminococcus* / *Clostridium*), *Blautia* (*Blautia*), *Sellimonas* (*Sellimonas* / *Drancourtella*),  
186 *Clostridium Q* (*Lachnoclostridium* [*Clostridium*]) and *Tyzzerella* (*Tyzzerella* / *Coprococcus*). Notably,  
187 all but one of the features in the main classification models (n226) were identified in the feature  
188 selection for the alternative models (constructed otherwise identically, but  $FLI < 30$  was compared  
189 against  $FLI \geq 60$  in different data partitions), together with 10 additional balances (**Figure S4**). Only  
190 one of the balances in the alternative models was outside phylum *Firmicutes* (n1712 in *Bacteroidota*),  
191 and in addition, 4 balances were outside class *Clostridia* (n481 in *Negativicutes*; n826, n1009 and n918  
192 in *Bacilli*).

193  
194 In addition to blood test results, FLI is based on anthropometric markers linked to metabolic syndrome,  
195 waist circumference and BMI. This prompted us to attempt to dissect the index and identify which of  
196 the covariates and associated microbial balances from the phylogenetic tree can be linked to blood  
197 GGT and triglycerides measurements (see **Figure 1B**), and therefore would be more specific to hepatic  
198 steatosis and liver damage. To do so, we performed feature selection (similarly to continuous FLI) for  
199 GGT and triglycerides measurements in subsets of participants grouped by age, sex, and BMI. The  
200 feature selection identified two balances within the NCBI *Clostridia* XIVa subcluster (identified as  
201 n336 and n330) which were important for both GGT and triglyceride level prediction, and thus likely  
202 specific to liver function (**Figure 2**). Bacterial taxa were positively linked to liver function in these  
203 balances, and included (NCBI species) *Clostridium clostridioforme*, *C. bolteae*, *C. citroniae*, *C.*  
204 *saccharolyticum* and *C. symbiosum*.



205

206 **Ethanol and acetate production pathways are identified in representative bacterial**  
207 **genomes from taxa linked to liver function**

208 The values of predictive balances in the phylogenetic tree cannot be summarized for individual taxa,  
209 which means that only a qualitative investigation of the associations between their metabolism and  
210 fatty liver was possible in this study. We identified genetic pathways predicted to encode for SCFA  
211 (acetate, propanoate, butanoate) and ethanol production, BA metabolism, and choline degradation to  
212 trimethylamine in representative genomes from the taxa we identified to be linked to liver function  
213 (**Figure S3**). These specific processes were chosen because they have been previously identified to  
214 have a mechanistic link to NAFLD (see *e.g.*, Safari and Gérard, 2019).

215

216 Acetate and ethanol production pathways appeared to be more abundant in the representative genomes  
217 of the taxa which had a positive association with FLI. In the liver function specific clades, n336 and  
218 n330, MetaCyc pathways for pyruvate fermentation to ethanol III (PWY-6587) and L-glutamate  
219 degradation V (via hydroxyglutarate; P162-PWY; produces acetate and butanoate) were present only in  
220 genomes positively associated with FLI. In balance n336, also heterolactic fermentation (P122-PWY;  
221 produces ethanol and lactate) was more often encoded in the FLI-associated clade (3/5) than the  
222 opposing clade (1/2). In representative genomes from the non-liver-specific balance n355, potential  
223 ethanol producers (PWY-6587) were seen in the positively associated clade, but for most balances such  
224 trends were not clear in the qualitative analysis. Furthermore, we did not detect any of these pathways  
225 in the representative genomes of two individual taxa positively associated with FLI, *Negativibacillus*  
226 *sp000435195* and *Phoceia massiliensis* (**Figure S3**).

227

## 228 Discussion

229 The pathophysiology of fatty liver disease in general, and NAFLD in particular, is complex and its  
230 clinical diagnosis can be difficult (Haas et al., 2016). In this study, we leveraged multi-omics data  
231 from a large population study (FINRISK02) to identify broad links between the overall gut  
232 microbiome composition and fatty liver disease, using FLI as a recognized proxy (**Figure 1C**), and  
233 identified specific microbial taxa and lineages predictive of a higher FLI (**Figure 2**). Considering that  
234 the predictive ability of FLI for clinically diagnosed NAFLD ranges between  $AUC = 0.81 - 0.93$ , in  
235 populations of Caucasian ethnicity such as ours (Vanni and Bugianesi, 2015), our models were able to  
236 reasonably predict the FLI group with  $AUC = 0.75$  ( $AUPRC = 0.56$ , baseline at 0.30), while  
237 extrapolating to a validation region not used in training of the model.

238

239 Our additional analyses support these results. Excluding participants with intermediate FLI (between  
240 30 – 60) increased the accuracy slightly (to  $AUC = 0.8$  and  $AUPRC = 0.75$ , baseline at 0.41).  
241 However, discerning between participants with probable fatty liver disease ( $FLI \geq 60$ ) from others  
242 presents a clinically more relevant target for detecting changes in microbiome composition associated  
243 with development of the disease. In another set of models, we negated the influence of validation  
244 region data in the individual models also for feature selection and hyperparameter optimization during  
245 training. This led to individualized sets of features and parameters in the models, but the average  
246 performance of the models was almost identical on validation region samples in the test data ( $AUC =$   
247  $0.75$  and  $AUPRC 0.57$ , baseline at 0.30). The aim of our study was to find patterns in microbiome  
248 composition which would be generalizable across the 6 sampled geographic regions in Finland and  
249 easy to interpret. Thus, we consider the use of all training data to define the common core feature set  
250 justified. This goal also guided our overall modeling architecture and likely led to a lower  
251 performance than if we instead performed interpolation within a smaller scale (*e.g.*, He et al., 2018).

252

253 When interpreting results, several different levels of associations can be considered according to  
254 types of fatty liver disease and the gut microbiome composition. Because FLI has been mostly  
255 validated with simple steatosis and NAFLD (Bedogni et al., 2006; Vanni and Bugianesi, 2015), we  
256 can conservatively contextualize our findings with previous associative work that used these  
257 diagnoses or clinical manifestations, only.

258

259 **FLI modeling reveals consistent associations between gram-positive *Clostridia* and fatty**  
260 **liver disease**

261 We found significant linear correlations between the first three bacterial PC-axes of our samples (a  
262 measure of beta diversity) and FLI (see results and Figure 1C). Previous studies have shown  
263 differences in beta diversity in relation to NAFLD (Kim et al., 2019). However, FLI used in our study  
264 as a proxy for liver disease also includes features such as BMI and waist circumference, which  
265 associate with metabolic syndrome and type 2 diabetes (Aron-Wisnewsky et al., 2020). Links  
266 between these diseases and gut microbiome composition are well documented in previous studies  
267 (Castaner et al., 2018). It is thus not surprising that bacterial beta diversity and FLI were correlated,  
268 but unfortunately this simple correlation does not enable untangling the relative contributions of fatty  
269 liver disease and other metabolic diseases to the differences in bacterial beta diversity.

270

271 Several studies have reported highly specific changes in microbial abundances in relation to NAFLD  
272 (Wigg et al., 2001; Mouzaki et al., 2013; Zhu et al., 2013; Shen et al., 2017). In summary, while also  
273 conflicting results have been reported, generally increases in *Lactobacillus* and *Escherichia* genera,  
274 and a decrease in *Coprococcus* genus have been most often associated with a NAFLD diagnosis  
275 (Sharpton et al., 2019). Furthermore, increased abundance of several gram-positive bacteria belonging

276 to the *Clostridium* genus have often been positively linked with NAFLD (Jiang et al., 2015; Loomba  
277 et al., 2017). Differences in unconstrained between-samples (beta) diversity have been also  
278 documented for persistent NAFLD (Kim et al., 2019) and along the NAFLD-cirrhosis spectrum  
279 (Caussy et al., 2019).

280

281 In our study, abundances of bacteria from the *Coprococcus* genus were not specifically associated  
282 with FLI, although the genus was nested inside our predictive balances. Strikingly, we did not  
283 identify any bacterial associations with FLI outside of the *Firmicutes* phylum. A possible reason for  
284 this might be the higher relative abundance of phylum *Firmicutes* at high latitudes, where Finland is  
285 (Suzuki and Worobey, 2014). Among the associations we identified, *Faecalibacterium gnavus* (NCBI:  
286 *Ruminococcus gnavus*) was positively linked with FLI as part of 3 predictive balances, and associated  
287 in previous studies with liver cirrhosis (Qin et al., 2014). Interestingly, none of the oral *Firmicutes*,  
288 such as *Veillonella*, suggested to invade the gut, were identified in our own analyses. This might be  
289 caused by using FLI as a proxy, which is likely not closely associated with advanced liver disease,  
290 such as cirrhosis, and thus would target an earlier phase of liver disease progression.

291

292 Two individual taxa, *Negativibacillus sp000435195* and *Phocecea massiliensis*, were highly predictive  
293 of FLI group (**Figures 2, S2**), but not of its liver function-specific components. The associations of  
294 these taxa with fatty liver disease have not been documented previously. However, a decreasing  
295 abundance of both bacteria, *Negativibacillus sp000435195* (NCBI: *Clostridium* sp. CAG:169) and  
296 *Phocecea massiliensis* (NCBI: *Phocecea massiliensis*), were seen when the intake of meat and refined  
297 cereal was reduced isocalorically in favor of fruit, vegetables, wholegrain cereal, legumes, fish and  
298 nuts in overweight and obese subjects in Italy (Meslier et al., 2020). While comparisons between  
299 these studies are difficult due to annotation, bacteria such as *Faecalibacterium gnavus* (NCBI:

300 *Ruminococcus gnavus*) and *Clostridium Q saccharolyticum* (NCBI: *Clostridium saccharolyticum*)  
301 were also found to respond negatively to the Mediterranean diet. Together with their positive  
302 association with FLI in our study, these observations would warrant further study on these species as  
303 plausible biomarkers for healthy diet choices.

304

305 Most taxa in our study with a positive association with FLI belonged to the (broadly defined)  
306 *Clostridium* NCBI genus, which supports several previous observations (Jiang et al., 2015; Loomba et  
307 al., 2017). However, taxonomic standardization according to GTDB has identified the *Clostridium*  
308 genus as the most phylogenetically inconsistent of all bacterial genera in the NCBI taxonomy, and  
309 divides it into a total of 121 monophyletic genera in 29 distinct families (Parks et al., 2018). These  
310 reassignments, although more accurate and sensible, complicate comparisons to previous research  
311 studies. However, our results strongly suggest that this finer taxonomic resolution might robustly  
312 reveal novel discoveries. Thus, while (shallow) shotgun metagenomic sequencing is often more costly  
313 than amplicon sequencing, this might be justified by the increased resolution which is required to  
314 accurately identify specific taxon-based associations (e.g., Hillmann et al., 2018, 2020).

315

### 316 **Bacterial taxa associated with a high FLI have a genetic potential to exacerbate the** 317 **development of fatty liver disease**

318 We identified several plausible new associations between individual taxa and clades of bacteria and  
319 fatty liver. All taxa were from class *Clostridia*, which are obligate anaerobes. We observed that  
320 reference genomes from the bacterial taxa positively associated with FLI in the liver-specific balances  
321 harbored several genetic pathways necessary for ethanol production. Specifically, genes predicted to  
322 enable the fermentation of pyruvate to ethanol (MetaCyc PWY-6587) appeared to be common.  
323 Endogenous production of ethanol has been known to both induce hepatic steatosis and increase

324 intestinal permeability (de Faria Ghetti et al., 2018) and several of the taxa identified in our study  
325 have also been experimentally shown to produce ethanol, such as *C. M asparagiforme*, *C. M bolteae*,  
326 *C. M clostridioforme* / *C. M clostridioforme A* (Mohan et al., 2006), and *C. Q Saccharolyticum*  
327 (Murray et al., 1982). The relative abundances of these putatively ethanol-producing taxa were  
328 predictive of FLI groups in previously unseen data. However, the self-reported alcohol consumption  
329 from the participants was not among the best predictors for the FLI groups, as it was excluded in the  
330 feature selection step.

331

332 All reference genomes from taxa positively associated with FLI in balance n330 harboured genes  
333 predicted to encode for the L-glutamate fermentation V (P162-PWY; **Figure S3**) pathway, which  
334 results in the production of acetate and butanoate. Glutamate fermentation could lead to increased  
335 microbial protein fermentation in the gut, which has been previously been linked with obesity,  
336 diabetes and NAFLD (Diether and Willing, 2019). Recently, the combined intake of fructose and  
337 microbial acetate production in the gut was experimentally observed to contribute to lipogenesis in  
338 the liver in a mouse model (Zhao et al., 2020). Interestingly, *C. Q saccharolyticum* (in our study, a  
339 FLI-associated species deriving from balance n330), was experimentally shown to ferment various  
340 carbohydrates, including fructose, to acetate, hydrogen, carbon dioxide, and ethanol (Murray et al.,  
341 1982). Furthermore, while our own pathway analysis did not detect BA modification pathways in the  
342 reference genome of *C. Q saccharolyticum*, a strain of this species has been highlighted as a probable  
343 contributor to NAFLD development through the synthesis of secondary BA (Jiao et al., 2019). The  
344 links between dietary intake and gene regulation, combined with microbial fermentation in the gut  
345 warrant further mechanistic experiments to elucidate their links with fatty liver, and likely other  
346 metabolic diseases.

347

348 Intriguingly, NAFLD-associated ethanol producing bacteria in previous cohort studies have all been  
349 gram-negatives, such as (NCBI-defined) *Klebsiella pneumoniae* (Yuan et al., 2019) and *Escherichia*  
350 *coli* (Zhu et al., 2013). In our population sample, instead of gram-negatives, bacteria from the *C. M*  
351 *bolteae*, *C. M clostridioforme* / *C. M clostridioforme A* and *C. M citroniae* species (linked in our  
352 study with FLI as deriving from balance n336) have been described as opportunistic pathogens  
353 (Dehoux et al., 2016), and are hypothesized to exacerbate fatty liver development similarly through  
354 endogenous ethanol production. This result suggests that geographical (He et al., 2018) and ethnic  
355 (Deschasaux et al., 2018) variability might also strongly affect gut microbiome composition and its  
356 associations with disease. In addition to putative endogenous ethanol producers, we identified other  
357 FLI-associated taxa deriving from balance n330, for which reference genomes harbored a genetic  
358 pathway predicted to encode for the ability to ferment L-lysine to acetate and butyrate. While the  
359 production of these SCFAs is often considered beneficial for gut health, other metabolism of  
360 proteolytic bacteria might negatively contribute to fatty liver disease (Canfora et al., 2019).

361  
362 Through modeling a previously validated risk index for fatty liver, we could associate specific  
363 members of the gut microbiome with the disease across geographical regions in this representative  
364 sample of the general population in Finland. In addition, sex and age of participants were also  
365 strongly predictive of the FLI group in our models (**Figures 2, S2, Table S1**). Their similar positive  
366 associations with fatty liver disease are known from previous studies (*e.g.*, Cheng et al., 2013;  
367 Lonardo et al., 2019). The associated microbial balances could be used to improve the predictions  
368 above the baseline of these covariates on 5/6 regions in Finland. For example, in the model cross-  
369 validated with Lapland the balances were more predictive of FLI group than the covariates by  
370 themselves, and their combination increased the AUC further. Yet, when testing the model where  
371 Turku/Loimaa region was used for cross-validation, the microbial balances were slightly predictive of



372 FLI group but failed to improve the AUC over the covariates (**Table S1**). This pattern might stem  
373 from the cultural and genetic west-east division in Finland (Näyhä, 1989; Kerminen et al., 2017), with  
374 a closer proximity of the Helsinki/Vantaa region to eastern regions than Turku/Loimaa, in both terms.  
375 It is thus likely that further incorporation and investigation on the use of spatial information in  
376 microbiome modeling would elucidate these geographical patterns in taxa-disease associations.

377

## 378 **Conclusions**

379 Modeling an established risk index for fatty liver enabled the detection of associations between the  
380 disease and gut microbiome composition, even to the level of individual taxa. These taxa and clades  
381 were all from the obligately anaerobic gram-positive class *Clostridia*, from several redefined GTDB  
382 genera previously included in the polyphyletic NCBI genus *Clostridium*. Many of the representative  
383 genomes of taxa positively associated with fatty liver had genomic potential for endogenous ethanol  
384 production. This suggests a possible mechanistic link to the pathophysiology of liver disease through  
385 increased gut permeability and induction of hepatic steatosis. Further mechanistic links with  
386 microbial production of SCFAs, especially acetate, and fatty liver development are also likely. Our  
387 models were able to predict the FLI group of participants across geographical regions in Finland,  
388 showing that the associations are robust and mostly generalizable in the sampled population.

389

## 390 **Methods**

### 391 **Survey details and sample collection**

392 Cardiovascular disease risk factors have been monitored in Finland since 1972 by conducting a  
393 representative population survey every five years (Borodulin et al., 2018). In the FINRISK 2002  
394 survey, a stratified random population sample was conducted on six geographical regions in Finland.

395 These are North Karelia and Northern Savo in eastern Finland, Turku and Loimaa regions in  
396 southwestern Finland, the cities of Helsinki and Vantaa in the capital region, the provinces of Northern  
397 Ostrobothnia and Kainuu in northwestern Finland, and the province of Lapland in northern Finland.

398

399 Briefly, at baseline examination the participants filled out a questionnaire form, and trained nurses  
400 carried out a physical examination and blood sampling in local health centers or other survey sites.  
401 Data was collected for physiological measures, biomarkers, and dietary, demographic and lifestyle  
402 factors. Stool samples were collected by giving willing participants a stool sampling kit with detailed  
403 instructions. These samples were mailed overnight between Monday and Thursday under Finnish  
404 winter conditions to the laboratory of the Finnish Institute for Health and Welfare, where they were  
405 stored at -20°C. In 2017, the samples were shipped still unthawed to University of California San Diego  
406 for microbiome sequencing.

407

408 Further details of the FINRISK cohorts and sampling have been extensively covered in previous  
409 publications (Borodulin et al., 2015; Salosensaari et al., 2020). The Coordinating Ethics Committee of  
410 the Helsinki University Hospital District approved our study protocol. All participants have given their  
411 written informed consent.

412

### 413 **Stool DNA extraction and shallow shotgun metagenome sequencing**

414 A miniaturized version of the Kapa HyperPlus Illumina-compatible library prep kit (Kapa Biosystems)  
415 was used for library generation, following the previously published protocol (Sanders et al., 2019).  
416 DNA extracts were normalized to 5 ng total input per sample in an Echo 550 acoustic liquid handling  
417 robot (Labcyte Inc). A Mosquito HV liquid-handling robot (TTP Labtech Inc was used for 1/10 scale  
418 enzymatic fragmentation, end-repair, and adapter-ligation reactions). Sequencing adapters were based

419 on the iTru protocol (Glenn et al., 2019), in which short universal adapter stubs are ligated first and  
420 then sample-specific barcoded sequences added in a subsequent PCR step. Amplified and barcoded  
421 libraries were then quantified by the PicoGreen assay and pooled in approximately equimolar ratios  
422 before being sequenced on an Illumina HiSeq 4000 instrument to an average read count of  
423 approximately 900,000 reads per sample.

424

### 425 **Taxonomic matching and phylogenetic transforms**

426 To improve the taxonomic assignments of our reads, we used a custom index (Méric et al., 2019) based  
427 on the Genome Taxonomy Database (GTDB) release 89 (Parks et al., 2018, 2020) taxonomic  
428 redefinitions for read classification with default parameters in Centrifuge 1.0.4 (Kim et al., 2016). After  
429 read classification, all following steps were performed with R version 3.5.2 (R Core Team, 2018). To  
430 reduce the number of spurious read assignments, and to facilitate more accurate phylogenetic  
431 transformations, only reads classified at the species level, matching individual GTDB reference  
432 genomes, were retained. Samples with less than 50,000 reads, from pregnant participants or recorded  
433 antibiotic use in the past 6 months were removed, resulting in a final number of 6,269 samples. We first  
434 filtered taxa not seen with more than 3 counts in at least 1% of samples and those with a coefficient of  
435 variation  $\leq 3$  across all samples, following (McMurdie and Holmes, 2013) with a slight adaption from  
436 20% of samples to 1% of samples, because of our larger sample size. The complete bacterial and  
437 archaeal phylogenetic trees of the GTDB release 89 reference genomes, constructed from an alignment  
438 of 120 bacterial or 122 archaeal marker genes (Parks et al., 2018), were then combined with our taxa  
439 tables. The resulting trees were thus subset only to species which were observed in at least one sample  
440 in our data. The read counts were transformed to phylogenetic node balances in both trees with PhILR  
441 (Silverman et al., 2017). The default method for PhILR inputs a pseudocount of 1 for taxa absent in an  
442 individual sample before the transform.

443

444 In this study, we did not specifically and solely use relative abundances at various taxonomic levels, as  
445 is common practice for microbiome studies. Instead, we applied a PhILR transformation to our  
446 microbial composition data (Silverman et al., 2017), introducing the concept of microbial “balances”.  
447 Indeed, evolutionary relationships of all species harbored in each microbiome sample can be  
448 represented on a phylogenetic tree, with species typically shown as external nodes that are related to  
449 each other by multiple branches connected by internal nodes. In this context, the value of a given  
450 microbial “balance” is defined as the log-ratio of the geometric mean abundance between two groups  
451 of microbes descending from the same corresponding internal node on a microbial phylogenetic tree.  
452 This phylogenetic transform was used because it i) addresses the compositionality of the metagenomic  
453 read data (Gloor et al., 2017), ii) permits simultaneous comparison of all clades without merging the  
454 taxa by predefined taxonomic levels, and iii) enables evolutionary insights into the microbial  
455 community. The links between microbes and their environment, such as the human gut, is mediated by  
456 their functions. Different functions are known to be conserved at different taxonomic resolutions, and  
457 most often at multiple different resolutions (Louca et al., 2018). Thus, associations between the  
458 microbes and the response variable are likely not best explained by predefined taxonomic levels. In the  
459 absence of functional data, concurrently analyzing all clades (partitioned by the nodes in the  
460 phylogenetic tree) would likely enable the detection of the associations at the appropriate resolution  
461 depending on the function and the local tree topography.

462

### 463 **Covariates**

464 Because fatty liver disease is underdiagnosed at the population level (Alexander et al., 2018) and our  
465 sampling did not have extensive coverage of liver fat measurements, we chose to use the Fatty Liver  
466 index (Bedogni et al., 2006) as a proxy for fatty liver. Furthermore, the index performs well in cohorts

467 of Caucasian ethnicity, such as ours, to diagnose the presence of NAFLD (Vanni and Bugianesi, 2015).  
468 We calculated FLI after Bedogni et al., (2006):  $(e^{0.953 \cdot \log_e(\text{triglycerides mg/dL}) + 0.139 \cdot \text{BMI} + 0.718 \cdot \log_e(\text{GGT}) +$   
469  $0.053 \cdot \text{waist circumference} - 15.745) / (1 + e^{0.953 \cdot \log_e(\text{triglycerides mg/dL}) + 0.139 \cdot \text{BMI} + 0.718 \cdot \log_e(\text{GGT}) + 0.053 \cdot \text{waist circumference} -$   
470  $15.745}) * 100$ . We chose the cutoff at  $\text{FLI} \geq 60$  to identify participants likely to be diagnosed with hepatic  
471 steatosis (positive likelihood ratio = 4.3 and negative likelihood ratio = 0.5 in Bedogni et al., 2006).  
472 Triglycerides, gamma glutamyl transferase (GGT), BMI and waist circumference measurements had  
473 near complete coverage for the participants in our data. Self-reported alcohol use was calculated as  
474 grams of pure ethanol per week. Cases with missing values were omitted in linear regression models.  
475 At least one feature used for FLI calculation was missing for 20 participants (0.3%) and the self-  
476 reported alcohol use was missing for 247 participants (3.9%). In the machine learning framework,  
477 missing values for FLI and self-reported alcohol use were mean imputed. However, for the feature  
478 selection to identify liver function-specific balances, GGT, triglycerides and BMI were not imputed but  
479 observations where any of these were missing were simply removed.

480

### 481 **Beta-diversity and linear modeling of FLI**

482 Beta-diversity was calculated as Euclidian distance of the PhILR balances through Principal  
483 Component Analysis (PCA) on bacterial and archaeal balances separately with ‘rda’ in vegan 2.5.6  
484 (Oksanen et al., 2018). A linear regression model was constructed for FLI with ‘lm’ in base R (R Core  
485 Team, 2018) with  $\log_{10}$ -transformed FLI as the dependent variable and with first three bacterial PCs,  
486 sex, age, and self-reported alcohol use as the independent variables. Archaeal PCs were dropped from  
487 the model because none of them were significantly correlated with FLI (all  $P > 0.05$ ). Variation of the  
488 samples on the top two bacterial PC axes by their effect sizes in the model were plotted together with a  
489 unit vector of  $\log_{10}(\text{FLI})$  to show their correlation.

490

## 491 **FLI modeling within a machine learning framework**

492 In the machine learning framework, both regression and categorical models were constructed for FLI.  
493 The feature selection, hyperparameter optimization and cross-validation methods were identical for  
494 both approaches, unless otherwise stated. The continuous or categorical FLI (groups of FLI < 60 and  
495 FLI  $\geq$  60) were modeled with xgboost 0.90.0.2 (Chen and Guestrin, 2016) by using both bacterial and  
496 archaeal balances, sex, age, and self-reported alcohol use as preliminary predictor features. We used  
497 FLI 60 as the cutoff for ruling in fatty liver (steatosis) for the classification, after Bedogni et al., (2006).  
498 The data was first split to 70% train and 30% test sets while preserving sex and region balance. To take  
499 into account geographical differences (*e.g.*, He et al., 2018) and to find robust patterns across all 6  
500 sampled regions in Finland between the features and FLI group, we used Leave-One-Group-Out Cross-  
501 Validation (LOGOCV) inside the 70% train set to construct 6 separate models in each optimization  
502 step. Because of high dimensionality of the data (3423 predictor features) feature selection by filtering  
503 was first performed inside the training data, based on random forest permutation as recommended by  
504 Bommert et al., (2020). Briefly, permutation importance is based on accuracy, or specifically the  
505 difference in accuracy between real and permuted (random) values of the specific variable, averaged in  
506 all trees across the whole random forest. The permutation importance in models based on the 6  
507 LOGOCV subsets of the training data were calculated with mlr 2.16.0 (Bischl et al., 2016) and the  
508 simple intersect between the top 50 features in all LOGOCV subsets were retained as the final set of  
509 features. Thus, the feature selection was influenced by the training data from all 6 geographical regions,  
510 but this only serves to limit the number of chosen features because of the required simple intersect.  
511 This approach was used to obtain a set of core predictive features which would have potential for  
512 generalizability across the regions. The number of features included in the models by this approach was  
513 deemed appropriate, since the relative effect size of the last included predictor was very small (< 0.1  
514 change in classification probability across its range).

515

516 Bayesian hyperparameter optimization of the xgboost models was then performed with only the  
517 selected features. An optimal set of parameters for the xgboost models were searched over all  
518 LOGOCV subsets with ‘mbo’ in mlrMBO 1.1.3 (Bischl et al., 2018), using 30 preliminary rounds with  
519 randomized parameters, followed by 100 optimization rounds. Parameters in the xgboost models and  
520 their considered ranges were learning rate (eta) [0.001, 0.3], gamma [0.1, 5], maximum depth of a tree  
521 [2, 8], minimum child weight [1, 10], fraction of data subsampled per each iteration [0.2, 0.8], fraction  
522 of columns subsampled per tree [0.2, 0.9], and maximum number of iterations (nrounds) [50, 5000].  
523 The parameters recommended by these searchers were as following for regression: eta=0.00889;  
524 gamma=2.08; max\_depth=2; min\_child\_weight=8; subsample=0.783; colsample\_bytree=0.672;  
525 nrounds=1810, and for classification: eta=0.00107; gamma=0.137; max\_depth=5;  
526 min\_child\_weight=9; subsample=0.207; colsample\_bytree=0.793; nrounds=4328. We used Root-  
527 Mean-Square Error (RMSE) for the regression models and Area Under the ROC Curve (AUC) for the  
528 classification models to measure model fit on the left-out data (region) in each LOGOCV subset. The  
529 final models were trained on the LOGOCV subset training data, the data from one region thus omitted  
530 per model, and using the selected features and optimized hyperparameters. Validation of these models  
531 was conducted against participants only from the region omitted from each model, in the 30% test data  
532 which was not used in model training or optimization. Sensitivity analysis was conducted by using only  
533 the predictive covariates (sex and age) or balances separately, with the same hyperparameters, data  
534 partitions and final validation as for the full models.

535

### 536 **Partial dependence interpretation of the FLI classification models**

537 Because the classification models have a more clinically relevant modeling target for the difference  
538 between  $FLI < 60$  and  $FLI \geq 60$ , the latter used to rule in fatty liver (Bedogni et al., 2006), we further



539 interpreted the partial dependence of their predictions. Partial dependence of the classification model  
540 predictions on individual features was calculated with ‘partial’ in pdp 0.7.0 (Greenwell, 2017). The  
541 partial dependence of the features on the model predictions was also plotted, overlaying the results  
542 from each of the 6 models. For each feature, its relative effect on the model prediction was estimated as  
543 medians of the minimum and maximum yhat (output probability of the model for the  $FLI \geq 60$  class),  
544 calculated at the minimum and maximum values of the feature separately in each of the 6 models. The  
545 relative effects of the balances were then overlaid as a heatmap on a genome cladogram which covers  
546 all balances in the model with ggtree 2.1.1 (Yu et al., 2017).

547

548 **Construction of alternative classification models to discern between**  
549 **FLI < 30 and FLI  $\geq$  60 groups**

550 To assess robustness of the models and how removing the participants with intermediate FLI (between  
551 30 and 60) affects model performance, we removed this group ( $N = 1910$ ) and constructed alternative  
552 classification models to discern between the  $FLI < 30$  and  $FLI \geq 60$  groups. Other than removing the  
553 intermediate FLI participants and resulting new random split to the train (70%) and test (30%) sets,  
554 these models were constructed identically to the main models, including LOGOCV design, feature  
555 selection, and hyperparameter optimization. The recommended parameters for this classification task  
556 were  $\eta=0.00102$ ;  $\gamma=3.7$ ;  $\max\_depth=2$ ;  $\min\_child\_weight=5$ ;  $subsample=0.49$ ;  
557  $colsample\_bytree=0.631$ ;  $nrounds=3119$ . Interpretation of partial dependence was also performed  
558 identically, but only the relative effects of the model features were plotted without a cladogram.

559

## 560 **Exclusion of validation region data from feature selection and hyperparameter**

### 561 **optimization**

562 Because training data from all 6 regions is used to inform the selection of optimal features and  
563 hyperparameters, the validation region data cannot be considered completely independent from the  
564 training of the LOGOCV models. Thus, we constructed a set of classification models for the  $FLI \geq 60$   
565 and  $FLI < 60$  groups, where all validation region samples also in the training data were excluded from  
566 the simple intercept of top50 features in each LOGOCV set and from the subsequent hyperparameter  
567 optimization. These models with individualized features and hyperparameters were then tested on the  
568 validation region samples in the unseen test data to estimate how model performance was affected. The  
569 main test (70%) and train (30%) sets were identical to the main models, but additionally 6 randomized  
570 70/30 splits nested inside the test set (excluding the validation region) were used in hyperparameter  
571 optimization to reduce overfitting. Average optimal hyperparameters in the 6 models were  
572  $\eta=0.00106$ ;  $\gamma=4.3$ ;  $\max\_depth=2$ ;  $\min\_child\_weight=7$ ;  $subsample=0.36$ ;  
573  $colsample\_bytree=0.613$ ;  $nrounds=1772$ .

574

### 575 **Identification of predictive features specific to liver function**

576 Because the FLI also incorporates BMI and waist circumference, and they strongly contribute to the  
577 index (Bedogni et al., 2006), we deemed it necessary to further investigate which of the identified  
578 balances were specific to liver function. The participants were first grouped by age ( $< 40$ ,  $40 - 60$ , and  
579  $60 <$ ), sex (female or male) and BMI ( $< 25$ ,  $25 - 30$ , and  $30 <$ ) into 18 categories ( $N = 105 \sim 711$  per  
580 category). We performed feature selection similarly to the FLI models by fitting random forest  
581 regressors for GGT and triglycerides with mlr 2.16.0 (Bischl et al., 2016). This was done separately in  
582 each of the 18 categories, and in each category, we again used LOGOCV with the regions to obtain 6  
583 runs per category. Finally, the features predictive of GGT or triglycerides in each category were

584 selected as the intersect of top 50 features in the 6 LOGOCV iterations by permutation importance. The  
585 intersect of features predictive of GGT or triglycerides in any of the categories and the features  
586 predictive of categorical FLI were identified as specific to liver function.

587

### 588 **Pathway inference for taxa associated with FLI**

589 Our taxonomic matching of the reads is based on the genomes of GTDB (release 89; Parks et al.,  
590 2018), which are all complete or nearly complete and available in online databases. This enables us to  
591 estimate the likely genetic content, and thus, the metabolic potential of the microbes associated with  
592 FLI. We use this approach because the sequencing depth of our samples does not allow assembling  
593 contigs and (metagenome-assembled) genomes, required for pathway predictions. Because of the  
594 compositional phylogenetic transform, among other features of our data, previously developed  
595 approaches such as PICRUSt (Douglas et al., 2019) could not be used here.

596

597 The genomes of all 336 bacteria under at least one of the predictive balances were downloaded from  
598 NCBI. 119 of these genomes were originally not annotated, which is a requirement for pathway  
599 prediction. Therefore, Prokka v1.14.6 (Seemann, 2014) was used to annotate the 119 unannotated  
600 genomes as a preliminary step. Pathway predictions were then performed for all 336 genomes with  
601 mpwt v0.5.3 (Belcour et al., 2019) multiprocessing tool for the PathoLogic pipeline of Pathway Tools  
602 23.0 (Karp et al., 2019). Pathways for ethanol and short chain fatty acid (acetate, butyrate, propionate)  
603 production, bile acid metabolism, and choline degradation to trimethylamine were identified from  
604 MetaCyc pathway classifications (Caspi et al., 2018; **Table S4**). The prevalence of these processes was  
605 then assessed in the analyzed genomes and summarized per process to consider the possible links of the  
606 taxa with fatty liver pathophysiology. Finally, the presence of individual pathways for acetate and  
607 ethanol production was also outlined for each genome.

608

## 609 **Declarations**

### 610 **Ethics approval and consent to participate**

611 The Coordinating Ethics Committee of the Helsinki University Hospital District approved our study  
612 protocol (Ref. 558/E3/2001). All participants have given their written informed consent.

### 613 **Consent for publication**

614 Not applicable.

### 615 **Availability of data and material**

616 The analysis code written for this study is included with the Supplementary Information. The datasets  
617 generated during and analyzed during the current study are not public, but are available based on a  
618 written application to the THL Biobank as instructed in: [https://thl.fi/en/web/thl-biobank/for-](https://thl.fi/en/web/thl-biobank/for-researchers)  
619 [researchers](https://thl.fi/en/web/thl-biobank/for-researchers)

### 620 **Competing interests**

621 V.S. has consulted for Novo Nordisk and Sanofi and received honoraria from these companies. He also  
622 has ongoing research collaboration with Bayer AG, all unrelated to this study. R.L. serves as a  
623 consultant or advisory board member for Anylam/Regeneron, Arrowhead Pharmaceuticals,  
624 AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myer Squibb, Celgene, Cirius, CohBar,  
625 Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse bio, GNI, GRI Bio, Inipharm, Intercept, Ionis,  
626 Janssen Inc., Merck, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer,  
627 Prometheus, Promethera, Sanofi, Siemens, and Viking Therapeutics. In addition, his institution has  
628 received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Cirius, Eli Lilly  
629 and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail,

630 Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma,  
631 Prometheus, and Siemens. He is also co-founder of Liponex, Inc.

## 632 **Funding**

633 This research was supported in part by grants from the Finnish Foundation for Cardiovascular  
634 Research, the Emil Aaltonen Foundation, the Paavo Nurmi Foundation, the Urmas Pekkala Foundation,  
635 the Finnish Medical Foundation, the Sigrid Juselius Foundation, the Academy of Finland (#321356 to  
636 A.H.; #295741, #307127 to L.L.; #321351 to T.N.) and the National Institutes of Health  
637 (R01ES027595 to M.J.). R.L. receives funding support from NIEHS (5P42ES010337), NCATS  
638 (5UL1TR001442), NIDDK (U01DK061734, R01DK106419, P30DK120515, R01DK121378,  
639 R01DK124318), and DOD PRCRP (W81XWH-18-2-0026). Additional support was provided by  
640 Illumina, Inc. and Janssen Pharmaceutica through their sponsorship of the Center for Microbiome  
641 Innovation at UCSD.


## 642 **Authors' contributions**

643 M.R., F.Å., V.M., V.S., R.K., L.L. and T.N. designed the work. A.H., L.V., G.M., P.J., V.S., M.J. and  
644 R.K. acquired the data. M.R., L.L. and T.N. analyzed the data. M.R. wrote the manuscript in  
645 consultation with all authors. M.I., P.J., V.S., R.K., L.L. and T.N. supervised the work. All authors  
646 gave final approval of the version to be published.


## 647 **Acknowledgements**

648 We thank all participants of the FINRISK 2002 survey for their contributions to this work, and Tara  
649 Schwartz for assistance with laboratory work.

## 650 Figures



651 **Figure 1.** Distribution of FLI (A), its components (B), and FLI in quantiles of the first three PC  
652 components of the fecal bacterial composition of the participants (C). The cutoff at FLI = 60 used to  
653 divide the participants is indicated with a dashed line in panels A and C.



654 **Figure 2.** Relative effects of predictive balances and covariates on the FLI < 60 and FLI ≥ 60  
 655 classification model (AUC = 0.75) predictions. Nodes of the balances are indicated in the cladogram  
 656 and the relative effect sizes of their clades (opposite sides of each balance) are shown in the associated  
 657 heatmap. The relative effect sizes of the covariates (age and sex) are shown below the legend with a  
 658 heatmap on the same scale as was used for the balances. The two liver-specific balances associated  
 659 with triglyceride and GGT levels are indicated with bold font. Clades with redundant information have  
 660 been collapsed but their major genera are indicated. The complete tree is included in **Figure S3**.



## 661 **References**

- 662 Alexander, M., Loomis, A. K., Fairburn-Beech, J., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra,  
663 D., et al. (2018). Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease.  
664 *BMC Medicine* 16, 130. doi:10.1186/s12916-018-1103-x.
- 665 Aron-Wisnewsky, J., Vigiotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., et al. (2020). Gut  
666 microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.  
667 *Nature Reviews Gastroenterology & Hepatology* 17, 279–297. doi:10.1038/s41575-020-0269-9.
- 668 Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., et al. (2006).  
669 The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general  
670 population. *BMC Gastroenterol* 6, 33. doi:10.1186/1471-230X-6-33.
- 671 Belcour, A., Frioux, C., Aite, M., Bretaudeau, A., and Siegel, A. (2019). Metage2Metabo: metabolic  
672 complementarity applied to genomes of large-scale microbiotas for the identification of  
673 keystone species. *bioRxiv*, 803056. doi:10.1101/803056.
- 674 Bischl, B., Lang, M., Kotthoff, L., Schiffner, J., Richter, J., Studerus, E., et al. (2016). mlr: Machine  
675 Learning in R. *Journal of Machine Learning Research* 17, 1–5.
- 676 Bischl, B., Richter, J., Bossek, J., Horn, D., Thomas, J., and Lang, M. (2018). mlrMBO: A Modular  
677 Framework for Model-Based Optimization of Expensive Black-Box Functions.  
678 *arXiv:1703.03373 [stat]*. Available at: <http://arxiv.org/abs/1703.03373> [Accessed February 18,  
679 2020].
- 680 Bommert, A., Sun, X., Bischl, B., Rahnenführer, J., and Lang, M. (2020). Benchmark for filter methods  
681 for feature selection in high-dimensional classification data. *Computational Statistics & Data  
682 Analysis* 143, 106839. doi:10.1016/j.csda.2019.106839.
- 683 Borodulin, K., Tolonen, H., Jousilahti, P., Jula, A., Juolevi, A., Koskinen, S., et al. (2018). Cohort  
684 Profile: The National FINRISK Study. *International Journal of Epidemiology* 47, 696–696i.  
685 doi:10.1093/ije/dyx239.
- 686 Borodulin, K., Vartiainen, E., Peltonen, M., Jousilahti, P., Juolevi, A., Laatikainen, T., et al. (2015).  
687 Forty-year trends in cardiovascular risk factors in Finland. *Eur J Public Health* 25, 539–546.  
688 doi:10.1093/eurpub/cku174.
- 689 Canfora, E. E., Meex, R. C. R., Venema, K., and Blaak, E. E. (2019). Gut microbial metabolites in  
690 obesity, NAFLD and T2DM. *Nature Reviews Endocrinology* 15, 261–273. doi:10.1038/s41574-  
691 019-0156-z.
- 692 Carpino, G., Del Ben, M., Pastori, D., Carnevale, R., Baratta, F., Overi, D., et al. (2019). Increased  
693 liver localization of lipopolysaccharides in human and experimental non-alcoholic fatty liver  
694 disease. *Hepatology*, hep.31056. doi:10.1002/hep.31056.
- 695 Caspi, R., Billington, R., Fulcher, C. A., Keseler, I. M., Kothari, A., Krummenacker, M., et al. (2018).  
696 The MetaCyc database of metabolic pathways and enzymes. *Nucleic Acids Res* 46, D633–  
697 D639. doi:10.1093/nar/gkx935.

- 698 Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., et al. (2019). A gut  
699 microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. *Nature*  
700 *Communications* 10, 1406. doi:10.1038/s41467-019-09455-9.
- 701 Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., et al. (2012). The  
702 diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the  
703 American Association for the Study of Liver Diseases, American College of Gastroenterology,  
704 and the American Gastroenterological Association. *Hepatology* 55, 2005–2023.  
705 doi:10.1002/hep.25762.
- 706 Chen, T., and Guestrin, C. (2016). XGBoost: A Scalable Tree Boosting System. *Proceedings of the*  
707 *22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining -*  
708 *KDD '16*, 785–794. doi:10.1145/2939672.2939785.
- 709 Cheng, H.-Y., Wang, H.-Y., Chang, W.-H., Lin, S.-C., Chu, C.-H., Wang, T.-E., et al. (2013).  
710 Nonalcoholic Fatty Liver Disease: Prevalence, Influence on Age and Sex, and Relationship with  
711 Metabolic Syndrome and Insulin Resistance. *International Journal of Gerontology* 7, 194–198.  
712 doi:10.1016/j.ijge.2013.03.008.
- 713 Compare, D., Coccoli, P., Rocco, A., Nardone, O. M., De Maria, S., Cartenì, M., et al. (2012). Gut–  
714 liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. *Nutrition,*  
715 *Metabolism and Cardiovascular Diseases* 22, 471–476. doi:10.1016/j.numecd.2012.02.007.
- 716 de Faria Ghetti, F., Oliveira, D. G., de Oliveira, J. M., de Castro Ferreira, L. E. V. V., Cesar, D. E., and  
717 Moreira, A. P. B. (2018). Influence of gut microbiota on the development and progression of  
718 nonalcoholic steatohepatitis. *Eur J Nutr* 57, 861–876. doi:10.1007/s00394-017-1524-x.
- 719 Dehoux, P., Marvaud, J. C., Abouelleil, A., Earl, A. M., Lambert, T., and Dauga, C. (2016).  
720 Comparative genomics of *Clostridium bolteae* and *Clostridium clostridioforme* reveals species-  
721 specific genomic properties and numerous putative antibiotic resistance determinants. *BMC*  
722 *Genomics* 17, 819. doi:10.1186/s12864-016-3152-x.
- 723 Deschasaux, M., Bouter, K. E., Prodan, A., Levin, E., Groen, A. K., Herrema, H., et al. (2018).  
724 Depicting the composition of gut microbiota in a population with varied ethnic origins but  
725 shared geography. *Nature Medicine* 24, 1526–1531. doi:10.1038/s41591-018-0160-1.
- 726 Diether, N. E., and Willing, B. P. (2019). Microbial Fermentation of Dietary Protein: An Important  
727 Factor in Diet–Microbe–Host Interaction. *Microorganisms* 7.  
728 doi:10.3390/microorganisms7010019.
- 729 Douglas, G. M., Maffei, V. J., Zaneveld, J., Yurgel, S. N., Brown, J. R., Taylor, C. M., et al. (2019).  
730 PICRUSt2: An improved and extensible approach for metagenome inference. *bioRxiv*, 672295.  
731 doi:10.1101/672295.
- 732 Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., and Knight, R. (2018).  
733 Current understanding of the human microbiome. *Nat. Med.* 24, 392–400.  
734 doi:10.1038/nm.4517.

- 735 Glenn, T. C., Nilsen, R. A., Kieran, T. J., Sanders, J. G., Bayona-Vásquez, N. J., Finger, J. W., et al.  
736 (2019). Adapterama I: universal stubs and primers for 384 unique dual-indexed or 147,456  
737 combinatorially-indexed Illumina libraries (iTru & iNext). *PeerJ* 7, e7755.  
738 doi:10.7717/peerj.7755.
- 739 Gloor, G. B., Macklaim, J. M., Pawlowsky-Glahn, V., and Egozcue, J. J. (2017). Microbiome Datasets  
740 Are Compositional: And This Is Not Optional. *Front Microbiol* 8.  
741 doi:10.3389/fmicb.2017.02224.
- 742 Greenwell, B. M. (2017). pdp: An R Package for Constructing Partial Dependence Plots. *The R Journal*  
743 9, 421–436.
- 744 Haas, J. T., Francque, S., and Staels, B. (2016). Pathophysiology and Mechanisms of Nonalcoholic  
745 Fatty Liver Disease. *Annual Review of Physiology* 78, 181–205. doi:10.1146/annurev-physiol-  
746 021115-105331.
- 747 He, Y., Wu, W., Zheng, H.-M., Li, P., McDonald, D., Sheng, H.-F., et al. (2018). Regional variation  
748 limits applications of healthy gut microbiome reference ranges and disease models. *Nature*  
749 *Medicine* 24, 1532–1535. doi:10.1038/s41591-018-0164-x.
- 750 Hillmann, B., Al-Ghalith, G. A., Shields-Cutler, R. R., Zhu, Q., Gohl, D. M., Beckman, K. B., et al.  
751 (2018). Evaluating the Information Content of Shallow Shotgun Metagenomics. *mSystems* 3.  
752 doi:10.1128/mSystems.00069-18.
- 753 Hillmann, B., Al-Ghalith, G. A., Shields-Cutler, R. R., Zhu, Q., Knight, R., and Knights, D. (2020).  
754 SHOGUN: a modular, accurate, and scalable framework for microbiome quantification.  
755 *Bioinformatics*, btaa277. doi:10.1093/bioinformatics/btaa277.
- 756 Jiang, W., Wu, N., Wang, X., Chi, Y., Zhang, Y., Qiu, X., et al. (2015). Dysbiosis gut microbiota  
757 associated with inflammation and impaired mucosal immune function in intestine of humans  
758 with non-alcoholic fatty liver disease. *Sci Rep* 5, 8096. doi:10.1038/srep08096.
- 759 Jiao, N., Wu, D., Yang, Z., Fang, S., Li, X., Yuan, M., et al. (2019). Gut bacteria contributes to  
760 NAFLD pathogenesis by promoting secondary bile acids biosynthesis. *The FASEB Journal* 33,  
761 126.4-126.4. doi:10.1096/fasebj.2019.33.1\_supplement.126.4.
- 762 Karp, P. D., Midford, P. E., Billington, R., Kothari, A., Krummenacker, M., Latendresse, M., et al.  
763 (2019). Pathway Tools version 23.0 update: software for pathway/genome informatics and  
764 systems biology. *Briefings in Bioinformatics*, bbz104. doi:10.1093/bib/bbz104.
- 765 Kerminen, S., Havulinna, A. S., Hellenthal, G., Martin, A. R., Sarin, A.-P., Perola, M., et al. (2017).  
766 Fine-Scale Genetic Structure in Finland. *G3: Genes, Genomes, Genetics* 7, 3459–3468.  
767 doi:10.1534/g3.117.300217.
- 768 Kim, D., Song, L., Breitwieser, F. P., and Salzberg, S. L. (2016). Centrifuge: rapid and sensitive  
769 classification of metagenomic sequences. *Genome Res.* doi:10.1101/gr.210641.116.

- 770 Kim, H.-N., Joo, E.-J., Cheong, H. S., Kim, Y., Kim, H.-L., Shin, H., et al. (2019). Gut Microbiota and  
771 Risk of Persistent Nonalcoholic Fatty Liver Diseases. *Journal of Clinical Medicine* 8, 1089.  
772 doi:10.3390/jcm8081089.
- 773 Koehler, E. M., Schouten, J. N. L., Hansen, B. E., Hofman, A., Stricker, B. H., and Janssen, H. L. A.  
774 (2013). External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver  
775 Disease in a Population-based Study. *Clinical Gastroenterology and Hepatology* 11, 1201–  
776 1204. doi:10.1016/j.cgh.2012.12.031.
- 777 Liu, Y., Meric, G., Havulinna, A. S., Teo, S. M., Ruuskanen, M., Sanders, J., et al. (2020). Early  
778 prediction of liver disease using conventional risk factors and gut microbiome-augmented  
779 gradient boosting. *Genetic and Genomic Medicine* doi:10.1101/2020.06.24.20138933.
- 780 Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T. A., et al. (2019). Sex  
781 Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research  
782 Gaps. *Hepatology* 70, 1457–1469. doi:10.1002/hep.30626.
- 783 Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., et al. (2017). Gut Microbiome-  
784 Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human  
785 Nonalcoholic Fatty Liver Disease. *Cell Metabolism* 25, 1054-1062.e5.  
786 doi:10.1016/j.cmet.2017.04.001.
- 787 Louca, S., Polz, M. F., Mazel, F., Albright, M. B. N., Huber, J. A., O'Connor, M. I., et al. (2018).  
788 Function and functional redundancy in microbial systems. *Nat Ecol Evol* 2, 936–943.  
789 doi:10.1038/s41559-018-0519-1.
- 790 Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., et al. (2003).  
791 Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 37, 917–923.  
792 doi:10.1053/jhep.2003.50161.
- 793 McMurdie, P. J., and Holmes, S. (2013). phyloseq: An R package for reproducible interactive analysis  
794 and graphics of microbiome census data. *PLoS ONE* 8, e61217.  
795 doi:10.1371/journal.pone.0061217.
- 796 Méric, G., Wick, R. R., Watts, S. C., Holt, K. E., and Inouye, M. (2019). Correcting index databases  
797 improves metagenomic studies. *bioRxiv*, 712166. doi:10.1101/712166.
- 798 Meslier, V., Laiola, M., Roager, H. M., Filippis, F. D., Roume, H., Quinquis, B., et al. (2020).  
799 Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and  
800 causes changes in the gut microbiome and metabolome independently of energy intake. *Gut*.  
801 doi:10.1136/gutjnl-2019-320438.
- 802 Miele, L., Valenza, V., Torre, G. L., Montalto, M., Cammarota, G., Ricci, R., et al. (2009). Increased  
803 intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.  
804 *Hepatology* 49, 1877–1887. doi:10.1002/hep.22848.
- 805 Mohan, R., Namsolleck, P., Lawson, P. A., Osterhoff, M., Collins, M. D., Alpert, C.-A., et al. (2006).  
806 *Clostridium asparagiforme* sp. nov., isolated from a human faecal sample. *Systematic and*  
807 *Applied Microbiology* 29, 292–299. doi:10.1016/j.syapm.2005.11.001.

- 808 Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., et al. (2013).  
809 Intestinal microbiota in patients with nonalcoholic fatty liver disease. *Hepatology* 58, 120–127.  
810 doi:10.1002/hep.26319.
- 811 Murray, W. D., Khan, A. W., and van den BERG, L. (1982). *Clostridium saccharolyticum* sp. nov., a  
812 Saccharolytic Species from Sewage Sludge. *International Journal of Systematic Bacteriology*  
813 32, 132–135. doi:10.1099/00207713-32-1-132.
- 814 Näyhä, S. (1989). Geographical variations in cardiovascular mortality in Finland, 1961-1985. *Scand J*  
815 *Soc Med Suppl* 40, 1–48.
- 816 Oksanen, J., Blanchet, F. G., Friendly, M., Kindt, R., Legendre, P., McGlinn, D., et al. (2018). *vegan*:  
817 *Community Ecology Package*. Available at: <https://CRAN.R-project.org/package=vegan>  
818 [Accessed June 4, 2018].
- 819 Parks, D. H., Chuvochina, M., Chaumeil, P.-A., Rinke, C., Mussig, A. J., and Hugenholtz, P. (2020). A  
820 complete domain-to-species taxonomy for Bacteria and Archaea. *Nature Biotechnology*, 1–8.  
821 doi:10.1038/s41587-020-0501-8.
- 822 Parks, D. H., Chuvochina, M., Waite, D. W., Rinke, C., Skarszewski, A., Chaumeil, P.-A., et al.  
823 (2018). A standardized bacterial taxonomy based on genome phylogeny substantially revises  
824 the tree of life. *Nat Biotechnol* 36, 996–1004. doi:10.1038/nbt.4229.
- 825 Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., et al. (2014). Alterations of the human gut  
826 microbiome in liver cirrhosis. *Nature* 513, 59–64. doi:10.1038/nature13568.
- 827 R Core Team (2018). *R: A language and environment for statistical computing*. Vienna, Austria: R  
828 Foundation for Statistical Computing Available at: <https://www.R-project.org/> [Accessed  
829 March 4, 2019].
- 830 Rinella, M., and Charlton, M. (2016). The globalization of nonalcoholic fatty liver disease: Prevalence  
831 and impact on world health. *Hepatology* 64, 19–22. doi:10.1002/hep.28524.
- 832 Safari, Z., and Gérard, P. (2019). The links between the gut microbiome and non-alcoholic fatty liver  
833 disease (NAFLD). *Cell. Mol. Life Sci.* 76, 1541–1558. doi:10.1007/s00018-019-03011-w.
- 834 Salosensaari, A., Laitinen, V., Havulinna, A. S., Meric, G., Cheng, S., Perola, M., et al. (2020).  
835 Taxonomic Signatures of Long-Term Mortality Risk in Human Gut Microbiota. *Epidemiology*  
836 doi:10.1101/2019.12.30.19015842.
- 837 Sanders, J. G., Nurk, S., Salido, R. A., Minich, J., Xu, Z. Z., Zhu, Q., et al. (2019). Optimizing  
838 sequencing protocols for leaderboard metagenomics by combining long and short reads.  
839 *Genome Biology* 20, 226. doi:10.1186/s13059-019-1834-9.
- 840 Seemann, T. (2014). Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30, 2068–2069.  
841 doi:10.1093/bioinformatics/btu153.



- 842 Sharpton, S. R., Ajmera, V., and Loomba, R. (2019). Emerging Role of the Gut Microbiome in  
843 Nonalcoholic Fatty Liver Disease: From Composition to Function. *Clinical Gastroenterology*  
844 *and Hepatology* 17, 296–306. doi:10.1016/j.cgh.2018.08.065.
- 845 Shen, F., Zheng, R.-D., Sun, X.-Q., Ding, W.-J., Wang, X.-Y., and Fan, J.-G. (2017). Gut microbiota  
846 dysbiosis in patients with non-alcoholic fatty liver disease. *Hepatobiliary & Pancreatic*  
847 *Diseases International* 16, 375–381. doi:10.1016/S1499-3872(17)60019-5.
- 848 Silverman, J. D., Washburne, A. D., Mukherjee, S., and David, L. A. (2017). A phylogenetic transform  
849 enhances analysis of compositional microbiota data. *eLife* 6, e21887. doi:10.7554/eLife.21887.
- 850 Spencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M., Zeisel, S. H., and Fodor, A. A. (2011).  
851 Association Between Composition of the Human Gastrointestinal Microbiome and  
852 Development of Fatty Liver With Choline Deficiency. *Gastroenterology* 140, 976–986.  
853 doi:10.1053/j.gastro.2010.11.049.
- 854 Suzuki, T. A., and Worobey, M. (2014). Geographical variation of human gut microbial composition.  
855 *Biology Letters* 10, 20131037. doi:10.1098/rsbl.2013.1037.
- 856 Toshikuni, N., Tsutsumi, M., and Arisawa, T. (2014). Clinical differences between alcoholic liver  
857 disease and nonalcoholic fatty liver disease. *World J Gastroenterol* 20, 8393–8406.  
858 doi:10.3748/wjg.v20.i26.8393.
- 859 Vanni, E., and Bugianesi, E. (2015). Editorial: utility and pitfalls of Fatty Liver Index in epidemiologic  
860 studies for the diagnosis of NAFLD. *Aliment Pharmacol Ther* 41, 406–407.  
861 doi:10.1111/apt.13063.
- 862 Wigg, A. J., Roberts-Thomson, I. C., Dymock, R. B., McCarthy, P. J., Grose, R. H., and Cummins, A.  
863 G. (2001). The role of small intestinal bacterial overgrowth, intestinal permeability,  
864 endotoxaemia, and tumour necrosis factor  $\alpha$  in the pathogenesis of non-alcoholic steatohepatitis.  
865 *Gut* 48, 206–211. doi:10.1136/gut.48.2.206.
- 866 Yki-Järvinen, H. (2014). Non-alcoholic fatty liver disease as a cause and a consequence of metabolic  
867 syndrome. *Lancet Diabetes Endocrinol* 2, 901–910. doi:10.1016/S2213-8587(14)70032-4.
- 868 Yu, G., Smith, D. K., Zhu, H., Guan, Y., and Lam, T. T.-Y. (2017). ggtree: an r package for  
869 visualization and annotation of phylogenetic trees with their covariates and other associated  
870 data. *Methods in Ecology and Evolution* 8, 28–36. doi:10.1111/2041-210X.12628.
- 871 Yuan, J., Chen, C., Cui, J., Lu, J., Yan, C., Wei, X., et al. (2019). Fatty Liver Disease Caused by High-  
872 Alcohol-Producing *Klebsiella pneumoniae*. *Cell Metabolism* 30, 675–688.e7.  
873 doi:10.1016/j.cmet.2019.08.018.
- 874 Zhao, S., Jang, C., Liu, J., Uehara, K., Gilbert, M., Izzo, L., et al. (2020). Dietary fructose feeds hepatic  
875 lipogenesis via microbiota-derived acetate. *Nature* 579, 586–591. doi:10.1038/s41586-020-  
876 2101-7.

877 Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., et al. (2013). Characterization of gut  
878 microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between  
879 endogenous alcohol and NASH. *Hepatology* 57, 601–609. doi:10.1002/hep.26093.